

In re Application of:

Schlom et al.

Art Unit: 1644

Application No. 10/725,373

Examiner: Marianne Nmn Dibrino

Filed: December 3, 2003

For: AGONIST AND ANTAGONIST PEPTIDES OF
CARCINOEMBRYONIC ANTIGEN (CEA)

SUBSTITUTE POWER OF ATTORNEY UNDER 37 CFR 3.71

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Government of the United States of America, represented by the Secretary, Department of Health and Human Services ("Assignee") is the assignee of the entire right, title, and interest in the above-identified U.S. patent application ("the application") as evidenced by the following:

An assignment from inventors Jeffrey Schlom, Elena Barzaga (also known as Elena Salazar), and Sam Zaremba to the Government of the United States of America, represented by the Secretary, Department of Health and Human Services was recorded in the U.S. Patent and Trademark Office on June 26, 2001, at Reel 011938, Frame No. 0914 with respect to prior U.S. Application No. 09/529,121 of which the above-identified application is a continuation.

In accordance with 37 CFR 3.73(b), the undersigned certifies that the undersigned is authorized to act on behalf of the assignee, has reviewed all of the evidentiary documents accompanying or referred to in this Substitute Power of Attorney and, to the best of the undersigned's knowledge and belief, that title is in the Assignee.

The Assignee hereby revokes all previous powers of attorney and appoints the following attorneys and patent agents of the National Institutes of Health, Office of

In re Appln. of Schlom et al.
Application No. 10/725,373

Technology Transfer, and of Leydig, Voit & Mayer, Ltd., who are identified with the following Customer Number, to prosecute and transact all business in the U.S. Patent and Trademark Office connected with the application, including but not limited to receiving all documents issued by the U.S. Patent and Trademark Office based thereon, filing continuation, continuation-in-part, and divisional applications based thereon, paying any and all fees, including maintenance fees for any resulting patent, filing for reissues and extensions of any resulting patent, and requesting reexamination of any resulting patent:

45733

The assignee further requests that correspondence concerning this application be directed to Leydig, Voit & Mayer, Ltd., as Customer Number:

45733

The assignee also requests that all telephone calls be directed to Leydig, Voit & Mayer, Ltd. at (312) 616-5600.

Respectfully submitted,

Michelle A. Booden
Michelle A. Booden, Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd., Suite 325
Rockville, MD 20852-3804
(301) 451-7337

Date: 21 June 2007